OBJECTIVE: Results of previous studies investigating the association between GCA and malignancy are conflicting. We performed a study of the risk of cancer in patients with biopsy-proven GCA. METHODS: Patients with biopsy-proven GCA were identified from pathology reports of temporal artery biopsies from the major pathology laboratories in South Australia (SA). All subjects with biopsy-proven GCA were linked to the SA Cancer Registry to identify cases of cancer until 31 December 2006. Standardized incidence ratios (SIRs) for cancer were determined using the age- and gender-specific rates for SA. RESULTS: There were 226 cases of biopsy-proven GCA (163 females and 63 males). Thirty-one cases were diagnosed with cancer, following the diagnosis of biopsy-proven GCA. There was no increased risk of cancer among those with biopsy-proven GCA, following the diagnosis of GCA compared with the general population (SIR 1.2; 95% CI 0.8, 1.6). CONCLUSION: This cohort study did not demonstrate any increased risk for malignancy in subjects with biopsy-proven GCA.
OBJECTIVE: Results of previous studies investigating the association between GCA and malignancy are conflicting. We performed a study of the risk of cancer in patients with biopsy-proven GCA. METHODS:Patients with biopsy-proven GCA were identified from pathology reports of temporal artery biopsies from the major pathology laboratories in South Australia (SA). All subjects with biopsy-proven GCA were linked to the SA Cancer Registry to identify cases of cancer until 31 December 2006. Standardized incidence ratios (SIRs) for cancer were determined using the age- and gender-specific rates for SA. RESULTS: There were 226 cases of biopsy-proven GCA (163 females and 63 males). Thirty-one cases were diagnosed with cancer, following the diagnosis of biopsy-proven GCA. There was no increased risk of cancer among those with biopsy-proven GCA, following the diagnosis of GCA compared with the general population (SIR 1.2; 95% CI 0.8, 1.6). CONCLUSION: This cohort study did not demonstrate any increased risk for malignancy in subjects with biopsy-proven GCA.
Authors: S Deshayes; E Liozon; N Chanson; K Sacré; T Moulinet; C Blanchard-Delaunay; O Espitia; M Groh; M Versini; T Le Gallou; J-E Kahn; V Grobost; S Humbert; M Samson; R Mourot Cottet; K Mazodier; A Dartevel; J Campagne; A Dumont; B Bienvenu; M Lambert; A Daumas; D Saadoun; A Aouba; H de Boysson Journal: Clin Rheumatol Date: 2019-01-07 Impact factor: 2.980
Authors: Amir Emamifar; Søren Hess; Torkell Ellingsen; Susan Due Kay; Jacob Christian Bang; Oke Gerke; Per Syrak Hansen; Ziba Ahangarani Farahani; Henrik Petersen; Niels Marcussen; Inger Marie Jensen Hansen; Peter Thye Rønn Journal: J Clin Med Date: 2020-12-04 Impact factor: 4.241